Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Xiaomin Liang & Yurong Lai. (2021) Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance. Expert Opinion on Drug Metabolism & Toxicology 17:8, pages 869-886.
Read now
Read now
Karen Rowland Yeo, Masoud Jamei & Amin Rostami-Hodjegan. (2013) Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Review of Clinical Pharmacology 6:2, pages 143-157.
Read now
Read now
Miyoung Yoon, Jerry L. Campbell, Melvin E. Andersen & Harvey J. Clewell. (2012) Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Critical Reviews in Toxicology 42:8, pages 633-652.
Read now
Read now
M. Moiz Mumtaz, Meredith Ray, Susan
R. Crowell, Deborah Keys, Jeffrey Fisher & Patricia Ruiz. (2012) Translational Research to Develop a Human PBPK Models Tool Kit—Volatile Organic Compounds (VOCs). Journal of Toxicology and Environmental Health, Part A 75:1, pages 6-24.
Read now
Read now
Jennifer B Dressman, Kirstin Thelen & Stefan Willmann. (2011) An update on computational oral absorption simulation. Expert Opinion on Drug Metabolism & Toxicology 7:11, pages 1345-1364.
Read now
Read now
Karen Rowland Yeo, Mohsen Aarabi, Masoud Jamei & Amin Rostami-Hodjegan. (2011) Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Review of Clinical Pharmacology 4:2, pages 261-274.
Read now
Read now
Melvin
E. Andersen, Mustafa Al-Zoughool, Maxine Croteau, Margit Westphal & Daniel Krewski. (2010) The Future of Toxicity Testing. Journal of Toxicology and Environmental Health, Part B 13:2-4, pages 163-196.
Read now
Read now
Pascal Espié, Dominique Tytgat, Maria-Laura Sargentini-Maier, Italo Poggesi & Jean-Baptiste Watelet. (2009) Physiologically based pharmacokinetics (PBPK). Drug Metabolism Reviews 41:3, pages 391-407.
Read now
Read now
Articles from other publishers (35)
Ananth K. Kammala, Lauren S. Richardson, Enkhtuya Radnaa, Arum Han & Ramkumar Menon. (2023) Microfluidic technology and simulation models in studying pharmacokinetics during pregnancy. Frontiers in Pharmacology 14.
Crossref
Crossref
Harsh Shah, Kushal Shah, Bhavin Gajera, Rutesh H. Dave & David R. Taft. (2023) Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug Albendazole. Pharmaceutics 15:4, pages 1040.
Crossref
Crossref
Jennifer H. Hammel, Jonathan M. Zatorski, Sophie R. Cook, Rebecca R. Pompano & Jennifer M. Munson. (2022) Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics. Advanced Drug Delivery Reviews 182, pages 114111.
Crossref
Crossref
Usman Ali Ashfaq, Farah Shahid & Samman Munir. 2022. Biochemistry of Drug Metabolizing Enzymes. Biochemistry of Drug Metabolizing Enzymes
29
72
.
P. Sucharitha, K. Ramesh Reddy, S.V. Satyanarayana & Tripta Garg. 2022. Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection. Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection
335
355
.
Sundus Khalid, Muhammad Fawad Rasool, Imran Imran, Abdul Majeed, Hamid Saeed, Anees ur Rehman, Waseem Ashraf, Tanveer Ahmad, Yousef A. Bin Jardan & Faleh Alqahtani. (2021) A Physiologically Based Pharmacokinetic Model for Predicting Diazepam Pharmacokinetics after Intravenous, Oral, Intranasal, and Rectal Applications. Pharmaceutics 13:9, pages 1480.
Crossref
Crossref
Fengxu Wu, Yuquan Zhou, Langhui Li, Xianhuan Shen, Ganying Chen, Xiaoqing Wang, Xianyang Liang, Mengyuan Tan & Zunnan Huang. (2020) Computational Approaches in Preclinical Studies on Drug Discovery and Development. Frontiers in Chemistry 8.
Crossref
Crossref
Michel Tod, Philippe B Pierrillas, Laurent Bourguignon & Sylvain Goutelle. (2016)
Comparison of the static
in vivo
approach to a physiologically based pharmacokinetic approach for metabolic drug–drug interactions prediction
. International Journal of Pharmacokinetics 1:1, pages 25-34.
Crossref
Crossref
Helene Chapy, Sylvie Klieber, Priscilla Brun, Sabine Gerbal-Chaloin, Xavier Boulenc & Olivier Nicolas. (2015) PBPK modeling of irbesartan: incorporation of hepatic uptake. Biopharmaceutics & Drug Disposition 36:8, pages 491-506.
Crossref
Crossref
Raj K. Singh Badhan. 2015. Computational Pharmaceutics. Computational Pharmaceutics
263
291
.
Barbara A. Wetmore. (2015) Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment. Toxicology 332, pages 94-101.
Crossref
Crossref
Huybrecht T’jollyn, Jan Snoeys, Pieter Colin, Jan Van Bocxlaer, Pieter Annaert, Filip Cuyckens, An Vermeulen, Achiel Van Peer, Karel Allegaert, Geert Mannens & Koen Boussery. (2014) Physiology-Based IVIVE Predictions of Tramadol from in Vitro Metabolism Data. Pharmaceutical Research 32:1, pages 260-274.
Crossref
Crossref
Christoph Giese & Uwe Marx. (2014) Human immunity in vitro — Solving immunogenicity and more. Advanced Drug Delivery Reviews 69-70, pages 103-122.
Crossref
Crossref
Carole E. Shardlow, Grant T. Generaux, Aarti H. Patel, Guoying Tai, Thuy Tran & Jackie C. Bloomer. (2013) Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development. Drug Metabolism and Disposition 41:12, pages 1994-2003.
Crossref
Crossref
Hui Zhou, Rong Shi, Bingliang Ma, Yueming Ma, Changhong Wang, Dazheng Wu, Xinhong Wang & Nengneng Cheng. (2013) CYP450 1A2 and multiple UGT1A isoforms are responsible for jatrorrhizine metabolism in human liver microsomes. Biopharmaceutics & Drug Disposition 34:3, pages 176-185.
Crossref
Crossref
Barbara A. Wetmore & Russell S. Thomas. 2013. High‐Throughput Screening Methods in Toxicity Testing. High‐Throughput Screening Methods in Toxicity Testing
77
95
.
Uwe Marx, Heike Walles, Silke Hoffmann, Gerd Lindner, Reyk Horland, Frank Sonntag, Udo Klotzbach, Dmitry Sakharov, Alexander Tonevitsky & Roland Lauster. (2012) ‘Human-on-a-chip’ Developments: A Translational Cutting-edge Alternative to Systemic Safety Assessment and Efficiency Evaluation of Substances in Laboratory Animals and Man?. Alternatives to Laboratory Animals 40:5, pages 235-257.
Crossref
Crossref
Manthena V. S. Varma, Yurong Lai, Bo Feng, John Litchfield, Theunis C. Goosen & Arthur Bergman. (2012) Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions. Pharmaceutical Research 29:10, pages 2860-2873.
Crossref
Crossref
Aki T. Heikkinen, Guillaume Baneyx, Antonello Caruso & Neil Parrott. (2012) Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus™. European Journal of Pharmaceutical Sciences 47:2, pages 375-386.
Crossref
Crossref
Stefan Willmann, Kirstin Thelen & Jörg Lippert. (2012) Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®. Journal of Pharmacy and Pharmacology 64:7, pages 997-1007.
Crossref
Crossref
François Bouzom, Kathryn Ball, Nathalie Perdaems & Bernard Walther. (2012) Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?. Biopharmaceutics & Drug Disposition 33:2, pages 55-71.
Crossref
Crossref
Moiz Mumtaz, Jeffrey Fisher, Benjamin Blount & Patricia Ruiz. (2012) Application of Physiologically Based Pharmacokinetic Models in Chemical Risk Assessment. Journal of Toxicology 2012, pages 1-11.
Crossref
Crossref
Barbara A. Wetmore, John F. Wambaugh, Stephen S. Ferguson, Mark A. Sochaski, Daniel M. Rotroff, Kimberly Freeman, Harvey J. ClewellIIIIII, David J. Dix, Melvin E. Andersen, Keith A. Houck, Brittany Allen, Richard S. Judson, Reetu Singh, Robert J. Kavlock, Ann M. Richard & Russell S. Thomas. (2012) Integration of Dosimetry, Exposure, and High-Throughput Screening Data in Chemical Toxicity Assessment. Toxicological Sciences 125:1, pages 157-174.
Crossref
Crossref
Annabelle Ballesta, Jean Clairambault, Sandrine Dulong & Francis Levi. 2012. New Challenges for Cancer Systems Biomedicine. New Challenges for Cancer Systems Biomedicine
301
327
.
Dorien A.M. van Dartel & Aldert H. Piersma. (2011) The embryonic stem cell test combined with toxicogenomics as an alternative testing model for the assessment of developmental toxicity. Reproductive Toxicology 32:2, pages 235-244.
Crossref
Crossref
Xavier Boulenc & Olivier Barberan. (2011) Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development. Drug Metabolism and Drug Interactions 26:4.
Crossref
Crossref
Feras Khalil & Stephanie Läer. (2011) Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug Development. Journal of Biomedicine and Biotechnology 2011, pages 1-13.
Crossref
Crossref
Xavier Boulenc, Wolfgang Schmider & Olivier Barberan. 2011. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology
133
160
.
Daniel M. Rotroff, Barbara A. Wetmore, David J. Dix, Stephen S. Ferguson, Harvey J. Clewell, Keith A. Houck, Edward L. LeCluyse, Melvin E. Andersen, Richard S. Judson, Cornelia M. Smith, Mark A. Sochaski, Robert J. Kavlock, Frank Boellmann, Matthew T. Martin, David M. Reif, John F. Wambaugh & Russell S. Thomas. (2010)
Incorporating Human Dosimetry and Exposure into High-Throughput
In Vitro
Toxicity Screening
. Toxicological Sciences 117:2, pages 348-358.
Crossref
Crossref
James M. Gallo. (2010) Pharmacokinetic/ Pharmacodynamic‐Driven Drug Development. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:4, pages 381-388.
Crossref
Crossref
Aki T. Heikkinen, Timo Korjamo, Varpu Lepikkö & Jukka Mönkkönen. (2010)
Effects of Experimental Setup on the Apparent Concentration Dependency of Active Efflux Transport in
in Vitro
Cell Permeation Experiments
. Molecular Pharmaceutics 7:2, pages 605-617.
Crossref
Crossref
Deepak Dalvie, Ping Kang, Michael Zientek, Cathie Xiang, Sue Zhou & R. Scott Obach. (2008) Effect of Intestinal Glucuronidation in Limiting Hepatic Exposure and Bioactivation of Raloxifene in Humans and Rats. Chemical Research in Toxicology 21:12, pages 2260-2271.
Crossref
Crossref
Michael B. Bolger, Robert Fraczkiewicz & Viera Lukacova. 2008. Drug Bioavailability. Drug Bioavailability
453
495
.
Hui-Xin Liu, Yong Liu, Jiang-Wei Zhang, Wei Li, Hong-Tao Liu & Ling Yang. (2008) UDP-Glucuronosyltransferase 1A6 Is the Major Isozyme Responsible for Protocatechuic Aldehyde Glucuronidation in Human Liver Microsomes. Drug Metabolism and Disposition 36:8, pages 1562-1569.
Crossref
Crossref
Yan-Guang Cao, Yuan-Cheng Chen, Kun Hao, Ming Zhang & Xiao-Quan Liu. (2008) An in Vivo Approach for Globally Estimating the Drug Flow between Blood and Tissue for Nafamostat Mesilate: the Main Hydrolysis Site Determination in Human. Biological and Pharmaceutical Bulletin 31:11, pages 1985-1989.
Crossref
Crossref